Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jul 22;23(1):259.
doi: 10.1186/s12882-022-02890-9.

The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial

Aida Lydia  1   2 , Tities Anggraeni Indra  3 , Aulia Rizka  4 , Murdani Abdullah  5
Affiliations
Randomized Controlled Trial

The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial

Aida Lydia et al. BMC Nephrol. .

Abstract

Background: Gut microbiota dysbiosis in patients with chronic kidney disease on haemodialysis (CKD-HD) creates an increase in proteolytic bacteria activity, leading to an increase in the production of uraemic toxins, such as indoxyl sulphate, worsening of constipation symptoms and reducing patients' quality of life. Improving gut microbiota dysbiosis is expected to improve this condition. This study aimed to evaluate the effect of synbiotics on indoxyl sulphate levels, constipation symptoms, and constipation-related quality of life in haemodialysis patients.

Methods: This was a double-blinded randomized controlled clinical trial with a parallel design involving haemodialysis patients. We included chronic haemodialysis patients with gastrointestinal complaints, difficulty defecating, faeces with hard consistency, or a bowel movement frequency of fewer than three times per week. Patients were randomly divided into two groups (synbiotics (Lactobacillus acidophilus and Bifidobacterium longum 5x109 CFU) and placebo) for 60 days of oral intervention. All participants, caregivers, and outcome assessors were blinded to group assignment. The primary outcome was a decrease in indoxyl sulphate toxin levels. Meanwhile, improvement in constipation symptoms (measured using the Patient Assessment of Constipation: Symptoms (PAC-SYM) questionnaire) and improvement in constipation-related quality of life (measured using the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire) were assessed as secondary outcomes.

Results: We included 60 patients (30 intervention; median age of 51.23 (13.57) years, 33.3% male; 30 control; median age of 52.33 (11.29) years, 36.7% male). There was no significant difference in terms of pre- and postintervention indoxyl sulphate toxin levels in the synbiotics group compared to the placebo group (p=0.438). This study found an improvement in constipation symptoms (p = 0.006) and constipation-related quality of life (p=0.001) after synbiotic administration.

Conclusion: Two months of synbiotic supplementation did not lower indoxyl sulphate toxin levels. Nevertheless, it had a major effect in improving constipation and quality of life affected by constipation in patients undergoing chronic haemodialysis.

Trial registration: NCT04527640 (date of first registration: 26/08/2020).

Keywords: Chronic kidney disease; Constipation; Haemodialysis; Indoxyl sulphate; Quality of life; Synbiotics.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Research algorithm according to Consolidated Standards of Reporting Trials (CONSORT)
See this image and copyright information in PMC

References

    1. Armani R, Ramezani A, Yasir A, et al. Gut microbiome in chronic kidney disease. Curr Hypertens Rep. 2017;19(4):29. doi: 10.1007/s11906-017-0727-0. - DOI - PubMed
    1. Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch Eur J Physiol. 2020;472:303–320. doi: 10.1007/s00424-020-02352-x. - DOI - PubMed
    1. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res. 2012;111(11):1470–1483. doi: 10.1161/CIRCRESAHA.112.278457. - DOI - PubMed
    1. Ramezani A, Massy ZA, Meijers B, et al. Role of the gut microbiome in Uremia: A potential therapeutic target. Am J Kidney Dis. 2016;67:483–498. doi: 10.1053/j.ajkd.2015.09.027. - DOI - PMC - PubMed
    1. Zuvela J, Trimingham C, Le Leu R, et al. Gastrointestinal symptoms in patients receiving dialysis: A systematic review. Nephrology. 2018;23:718–727. doi: 10.1111/nep.13243. - DOI - PubMed

Publication types

Associated data